Last updated: 11/07/2018 00:28:35
A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients
Trial description: A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: Benefit of fondaparinux in medical patients: a subgroup analysis. Cohen, AT , Gallus, AG, Davidson, BL , Lassen, MR , Prins, MH , Tomkowski, W , Turpie, AGG, Egberts, JFM , and Lensing, AWA 20th Congress of the International Society on Thrombosis and Haemostasis held jointly with the 51st Annual Meeting of the Scientific and Standardization Committee 8/6/2005 Sydney; Australia
Abstract: Fondaparinux for the prevention of vte in acutely ill medical patients. session type: oral session. Alexander T. Cohen, B. L. Davidson A. S. Gallus M. R. Lassen W. Tomkowski A. G. G. Turpie R. G. Cariou JEM. Egberts 45th Annual Meeting and Exposition of the American Society of Hematology 12/5/2003 San Diego, CA; USA
Abstract: Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (artemis). CohenA. T., Gallust A. S. Lassen M. R. Tomkowski W. TurpieT A. G. G. Davidsontt B. L. Cariou R. G. Lensing A. W. A. Egberts J. F. M. 19th Congress of the International Society on Thrombosis and Haemostasis and 49th Annual Scientific and Standardisation Committee Meeting 7/12/2003 Birmingham; UK
Abstract: Results of the ARTEMIS study. Cohen, A. T. , Davidson, B. L. , Gallus, A. S., Lassen, M. R. , Prins, M. H. , Tomkowski, W. , Turpie, A. G. G. , Egberts, J. F. M. , and Lensing, A. W. A. 21st World Congress of the International Union of Angiology 5/22/2004 Rome; Italy
Fondaparinux in medical patients: the ARTEMIS study. Blood 2003;102:abstract 42 AT Cohen
Thromboprophylaxis with fondaparinux in acutely ill medical patients aged 75 years or more. International Union of Angiology May 22-26, 2004 Rome, Italy Poster ARTEMIS Cohen
Thromboprophylaxis with fondaparinux in acutely ill medical patients with moderate renal impairment, Cohen, European Hematology Association, Geneva, Switzerland, June 10-13, 2004. ( poster)
Thromboprophylaxis with fondaparinux in acutely ill medical patients with moderate renal impairment. European Hematology Association June 10-13, 2004 Geneva, Switzerland Poster ARTEMIS Cohen
Thromboprophylaxis with fondaparinux in acutely ill medical patients with moderate renal impairment. International Union of Angiology May 22-26, 2004 Rome, Italy Poster ARTEMIS Cohen
Medical condition
Thromboembolism
Product
fondaparinux sodium
Collaborators
Not applicable
Study date(s)
January 2003 to November 2003
Type
Not applicable
Phase
2/3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2003-03-11
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website